HeyJaredLauren Biscaldi
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 24, 2026
- Outlet visibility, for Cancer Therapy Advisor
- Top 5M sites
- Earliest in this view
- Jul 22, 2026
Latest articles
Predicting NSAID Toxicity Risk in Inpatient, Outpatient Palliative Care (opens the original)
Read excerpt
Despite the presence of inflammatory pain stemming from cytokine and prostaglandin release, there is a lack of high-quality evidence on the safety and efficacy of nonsteroidal anti-inflammatory drug (NSAID) use in cancer settings. In addition to typical safety concerns associated with NSAID use — such as cardiovascular and gastrointestinal risks — concerns specific to patients with cancer include masking signs or symptoms of infection like fever. Although several NSAID-toxicity prediction models
Suzetrigine Changes Prescribing Patterns, Reduces Opioid Use for Acute Pain Management (opens the original)
Read excerpt
As US opioid overdose deaths continue to decrease — down nearly 14% in 2025 compared with 20241 — health care providers continue seeking nonopioid options for acute pain management Suzetrigine, approved in 20252 for moderate to severe acute pain, is poised to change the acute pain management paradigm. Approval was based on 2 Phase 3 clinical trials evaluating drug efficacy vs placebo. Suzetrigine is a novel analgesic that selectively targets and inhibits the Nav1.8 voltage-gated sodium channel t
Long-Term Opioid Prescription Fills Decrease Across Insurer Cohorts (opens the original)
Read excerpt
Opioid prescribing has generally decreased between 2010 and 2024, with variations based on duration of use and prescriber specialty, according to research results published in JAMA Network Open. As rates of opioid prescribing have decreased in response to the opioid epidemic, differentiating short- and long-term opioid prescribing is crucial as clinical decision-making, prescribing practices, and harm potential differ by indication. To learn more about how trends differ across medical specialtie
Vunakizumab Therapy Linked to Significant Improvement in Active r-axSpA (opens the original)
Read excerpt
Vunakizumab therapy is associated with significant improvement in signs and symptoms of radiographic axial spondyloarthritis (r-axSpA), according to research published in JAMA Network Open. In a randomized, double-blind, placebo-controlled phase 2/3 clinical trial, researchers evaluated the safety and efficacy of vunakizumab, a novel humanized IgG1 monoclonal antibody selectively targeting interleukin (IL)-17a, in people with active r-axSpA. Participants in the phase 2 trial were randomly assign
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Cancer Therapy Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.